The Innovative Medicines Initiative (IMI) has launched a new Call for proposals - Call 12

Call description:

Call ID:  H2020-JTI-IMI2-2017-11-single-stage

Action Type: RIA – Research and Innovation Actions

The Call includes the following topics:

- Topic 1: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)

- Topic 2: FAIRification of IMI and EFPIA data

- Topic 3: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)

- Topic 4: European health data network (EHDN)

- Topic 5: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations

- Topic 6: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

- Topic 7: European Screening Centre: unique library for attractive biology (ESCulab)

Internal deadline: 10 October 2017

Official deadline for submitting proposals: 24 October 2017 at 17:00

Find out more

All topic texts, Call documentation and details of how to apply can be found on the IMI website and in attachment.

Webinars

Webinars on all IMI2 – Call 12 topics, as well as IMI’s rules and procedures, have taken place and the presentations and recordings are available online

Tips on finding partners and preparing your proposal

The IMI website includes pages with advice for applicants and guidance on how to find project partners.

Why apply?

IMI Calls for proposals represent an excellent opportunity for researchers to take part in ground-breaking collaborative projects that aim to deliver tangible benefits for patients. Scientists from academia, industry, SMEs, mid-sized companies, hospitals and patients’ organisations are encouraged to get involved in our projects. Our success stories page offers a glimpse of the kinds of things IMI projects can achieve, and includes testimonials from project participants.

For more information, please do not hesitate to contact ajuts@vhir.org